Local view for "http://purl.org/linkedpolitics/eu/plenary/2011-04-07-Speech-4-065-000"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2011-04-07"^^xsd:date2
dcterms:Is Part Of	lp_eu:Vaccination against bluetongue (debate)2
dcterms:Language	"fr"^^xsd:language2
lpv:document identification number	"en.20110407.4.4-065-000"2
lpv:hasSubsequent	lp_eu:2011-04-07-Speech-4-066-0002
lpv:speaker	lp:Marc Tarabella2
lpv:spokenAs	member; FEMM (2009-09-17--2012-01-18)3 member; S&D (2009-07-16--2014-06-30)3 member; Delegation to the Parliamentary Assembly of the Union for the Mediterranean (2010-07-07--2014-06-30)3 unknown; Parti Socialiste (2009-07-16--2014-06-30)3 substitute; Delegation for relations with the United States (2009-09-16--2014-06-30)3 member; AGRI (2009-09-16--2012-01-18)3 substitute; Delegation to the Euro-Latin American Parliamentary Assembly (2009-10-07--2014-06-30)3 substitute; IMCO (2009-09-07--2012-01-18)3 member; Delegation for relations with the countries of Southeast Asia and the Association of Southeast Asian Nations (ASEAN) (2009-09-16--2014-06-30)3
lpv:translated text	"Mr President, Commissioner, ladies and gentlemen, I am grateful to our fellow Member, Mr Wojciechowski, for his report, which reminds us of the importance of appropriate legislation on this matter. However, whether the vaccine is live attenuated or inactivated, given the current state of our knowledge, blood tests do not enable us to identify how the pathogenic organism entered the animal’s blood – in other words, whether it originated in a vaccine or in the wild. Therefore, unless a marked inactivated vaccine – that is, a vaccine of which the pathogenic organism is of vaccine origin – is developed, it will be impossible to distinguish between a vaccinated animal and an animal infected by the virus. Yet that is an essential condition if a region or a country is to be declared safe from any contamination. There is a great risk, therefore, that countries that are protected from any contamination will put up trade barriers between themselves and countries that use that inactivated vaccine. Hence, the European Union has a duty to encourage ongoing research into a marked inactivated vaccine so as to ensure greater biosecurity within the Union, something which will enable us to combine our health and trade approaches more effectively."@en1
lpv:videoURI	<go to Events_and_structure europarl>2

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph